parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in cardiomyocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 835	0.85
pathways Reactome	5 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 6433

receipt 6441: CDH2 in dopamine neurons, braak

power: full sample +0.23 (p 0.351, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.29 (p 0.239, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.328, n 18). could be the mix.
skeptic: leave-one-out range +0.15 to +0.39, sign flips 0; without severely affected donors +0.23 (p 0.351, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CDH2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6440: CDH2 in oligodendrocytes, braak

power: full sample -0.14 (p 0.567, n 18), 95% CI -0.57 to +0.35. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.21 (p 0.398, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.22 (p 0.384, n 18). could be the mix.
skeptic: leave-one-out range -0.28 to -0.04, sign flips 0; without severely affected donors -0.14 (p 0.567, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CDH2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts